Occlusive Arterial Disease (OAD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Occlusive Arterial Disease (OAD) – Drugs In Development, 2024 report and make more profitable business decisions.
Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such as leg pain, cramping, or numbness during physical activity (claudication). The pain typically improves with rest but returns upon resuming activity. In severe cases, reduced blood flow can cause tissue damage, leading to non-healing ulcers or even gangrene. Factors contributing to the development of OAD include smoking, diabetes, high blood pressure, high cholesterol, obesity, ssedentary lifestyle, advanced age, and family history of cardiovascular disease.
The Occlusive Arterial Disease (OAD) drugs in development market research report provide comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Occlusive Arterial Disease (OAD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Occlusive Arterial Disease (OAD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 54 molecules, with 53 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Occlusive Arterial Disease (OAD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Occlusive Arterial Disease (OAD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Occlusive Arterial Disease (OAD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acclivity Technologies IncAlucent Biomedical Inc
Amplifier TX AB
AnGes Inc
Annexin Pharmaceuticals AB
AptaBio Therapeutics Inc
ARCA biopharma Inc
Athera Biotechnologies AB
Athersys Inc
Beijing Tide Pharmaceutical Co Ltd
BiogenCell Ltd
Cell Exosome Therapeutics Inc
CHA Biotech Co Ltd
Chengdu Shibeikang Biomedical Technology Co Ltd
Constant Therapeutics LLC
CuRAGE Therapeutics Inc
Exodos Life Sciences Limited Partnership
Exvastat Ltd
Foresee Pharmaceuticals Co Ltd
G&P Bioscience Co Ltd
Genovate Biotechnology Co LTD
Gurus BioPharm Inc
Helixmith Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
IsomAb Ltd
JanOne Inc
LipimetiX Development Inc
MediaPharma SRL
Nangiotx Inc
Northwestern University
Novo Nordisk AS
Pharmosa Biopharm Inc
Pluri Inc
Recardio Inc
Regio Biosciences
Resverlogix Corp
Reven Holdings Inc
Rnatives Inc
Sorrento Therapeutics Inc
Symic Bio Inc
Vasa Therapeutics SP Zoo
Vascugen Inc
Venturis Therapeutics Inc
VESSL Therapeutics Ltd
Vifor Pharma Management Ltd
Zelira Therapeutics Ltd
Zhittya Genesis Medicine Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Occlusive Arterial Disease (OAD) reports